Clinical trials: Bioavailability and Pharmacokinetics
Hereditary Angioedema Types I and II
A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor
A new formulation of Berinert (CSL830) is being investigated for the management of hereditary angioedema (HAE). The main aim of the study is to assess the safety of a single 1500 IU dose of the new formulation of Berinert.
- Trial name
- NCT01760343
- Testing
- Berinert, CSL830
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- CSL Behring
Healthy
An Investigation Of The Absorption And Pharmacokinetics Of Multiple Doses Of A Controlled Release Pregabalin Tablet As Compared To Multiple Doses Of The Immediate Release Pregabalin Capsule In Healthy Volunteers
The purpose of this study is to 1)evaluate the extent of absorption of multiple doses of a pregabalin controlled release tablet as compared to multiple doses of the pregabalin immediate release capsule, 2) evaluate the…
- Trial name
- NCT01257516
- Testing
- Pregabalin immediate release, 300 mg, Pregabalin controlled release, 330 mg
- Where
- Belgium
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Healthy
A Study to Investigate Efficacy and Safety of NSI-8226 in Healthy Participants
A Phase 1 Randomized, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Bioavailability of NSI-8226 in Healthy Participants.
- Trial name
- NCT06640920
- Testing
- Cohort A, Cohort B, Cohort C
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Uniquity One (UNI)
Bioavailability, Therapeutical Indication Not Studied
Nifedipine Bioavailability Study With Oral Single Doses Under Fasting and Fed Conditions
The present study will be performed to investigate and to compare the in-vivo performance of the two investigational products Gen-nifedipine extended release, (previously referred to as Gen-Nifedipine XL (Genpharm ULC, Canada))…
- Trial name
- NCT00884442
- Testing
- Nifedipine (Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL), Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS)
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- SocraTec R&D GmbH
Healthy Women of Child Bearing Potential
Assessment of Pharmacokinetics and Bioavailability of Carbon-14 ([14C])-Labelled Oxytocin
The current study is designed as a phase I multiple dose study to evaluate the pharmacokinetics and bioavailability of [14C]-labelled oxytocin in healthy women.
- Trial name
- NCT02911480
- Testing
- Oxytocin
- Volunteers
- healthy volunteers welcome
- Sponsor
- Oxytone Bioscience BV
Healthy
A 5-treatment, Study in Healthy Volunteers to Assess The Safety, Tolerability, and Pharmacokinetics of Four Controlled Release (CR) Pregabalin Tablet Formulations and the Immediate Release (IR) Formulation Administered Fasted
This study is an open-label, single dose, randomized, 5-period, 5-treatment, 4-sequence cross-over with a fixed 5th treatment arm.
- Trial name
- NCT01443169
- Testing
- Sequence 1 - Treatment A: Controlled Release Pregabalin, Sequence 1 - Treatment B: Controlled Release Pregabalin, Sequence 1 - Treatment C:Controlled Release Pregabalin
- Where
- Belgium
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Healthy Volunteers
3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of CC-220 in healthy subjects and to evaluate the relative bioavailability of a formulated CC-220 capsule
- Trial name
- NCT02034773
- Testing
- CC-220
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Celgene Corporation
Obesity, Morbid
Bariatric Surgery and Pharmacokinetics of Lisdexamphetamine
Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines.
- Trial name
- NCT03497169
- Testing
- Lisdexamfetamine Dimesylate
- Where
- Norway
- Volunteers
- 12 people
- Sponsor
- Norwegian University of Science and Technology
Healthy
14C-ARN-509 Microtracer Label AME and Absolute BA Study
This is study in healthy human volunteers to determine the absorption, metabolism, and excretion (AME) profile of ARN-509 as well as its absolute oral bioavailability (BA).
- Trial name
- NCT01822041
- Testing
- ARN-509
- Where
- Netherlands
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Aragon Pharmaceuticals, Inc.
Diabetes, Healthy
Safety and Tolerability of Liraglutide in Healthy Male Volunteers
This trial is conducted in Europe. The aim of this trial is to assess the safety and tolerability (maximum tolerated dose) after five ascending single doses of NNC 90-1170 (liraglutide).
- Trial name
- NCT01507272
- Testing
- liraglutide
- Where
- United Kingdom
- Volunteers
- 34 people
- Sponsor
- Novo Nordisk A/S
Healthy
Evaluation of Mass Balance and Absolute Bioavailability of GLPG1205
A study in healthy male volunteers to assess how the radiolabelled test medicine is taken up and broken down by the body when given by short infusion into a vein and when given by the mouth in the form of a capsule or tablet.
- Trial name
- NCT04704739
- Testing
- GLPG1205 film-coated tablets, [14C]-GLPG1205 solution for infusion, GLPG1205 capsules
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Healthy Volunteers
A Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers
This is a Phase I, randomized, two-part, single-center pharmacokinetics (PK) study to assess the relative bioavailability of capsule and tablet formulations of GDC-0941 in the fasted state (Part 1) and to determine the effect of…
- Trial name
- NCT00999128
- Testing
- GDC-0941, rabeprazole
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy Participants
A Study to Investigate the Relative Bioavailability of 2 Different Formulations of AZD4144, the Effect of Food and Omeprazole on the Pharmacokinetics of AZD4144 in Healthy Participants
The main aim of this study to compare the pharmacokinetics (PK) of two formulations of AZD4144 and assess the effect of food and omeprazole on PK of AZD4144 in healthy participants.
- Trial name
- NCT06948006
- Testing
- AZD4144, Omeprazole
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Nausea
Bioavailability Study of Anti Nausea Medication With and Without Food
This study is to assess the effect of food on a single dose of EUR-1025 when taken with a meal and taken on an empty stomach.
- Trial name
- EUR-1025 (NCT00905190)
- Testing
- Ondansetron
- Where
- Canada
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Forest Laboratories
Healthy Volunteers
Pharmacokinetics Of Celecoxib Test Formulations
The pharmacokinetics of new formulations of celecoxib are being evaluated. They are expected to provide more favorable bioavailability characteristics than the present commercial formulation.
- Trial name
- NCT00925106
- Testing
- Celebrex capsule, Test formulation D1, Test formulation D2
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hereditary Angioedema
A Relative Bioavailability Study of Two Formulations of BCX7353
This is an open-label, randomized study to investigate the relative bioavailability of two formulations of BCX7353 and to determine if there is a food effect
- Trial name
- NCT03202784
- Testing
- BCX7353
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- BioCryst Pharmaceuticals
Healthy
Pharmacokinetics/Bioavailability of BIBF 1120 Administered to Healthy Male Volunteers
Study to assess pharmacokinetics and the extend of absorption of a single dose of BIBF 1120 soft gelatine capsule with food effect (BA) in healthy subjects respectively.
- Trial name
- NCT02182076
- Testing
- BIBF 1120
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Clinical Trials, Phase I as Topic
BAY 1902607: Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Bioavailability, Food Effect
This study is a first-in-man study that will investigate the safety, tolerability and pharmacokinetics of ascending single doses of BAY1902607 using a placebo controlled, randomized, single center design.
- Trial name
- NCT03212586
- Testing
- BAY1902607
- Where
- Germany
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy Volunteer
Relative Bioavailability and Drug-drug Interaction Study With MT-7117 and a Proton Pump Inhibitor
An open label, multicentre, randomised, 2-cohort, sequential and crossover study to assess the relative oral bioavailability of MT-7117 higher content tablets versus MT-7117 lower content tablets and the pharmacokinetics of…
- Trial name
- MT-7117 BA DDI (NCT03688022)
- Testing
- MT-7117, PPI, Acidic beverage
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma America, Inc.
Healthy
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ACT-1004-1239 in Healthy Male Subjects
This Phase 1 study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of ACT-1004-1239 in healthy subjects.
- Trial name
- NCT03869320
- Testing
- ACT-1004-1239, ACT-1004-1239 (Food-effect subpart)
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.